-
Product Insights
Denovo Dental Inc, United States Revenue
GlobalData, the industry analysis specialist, has released its latest report: Denovo Dental Inc, United States Revenue. The medical devices sector is typified by frequent change and innovation in available devices, in response to demand from healthcare for ever more effective therapies and increased competition. As a result, the sector has seen the emergence of start-up medtech companies who are producing the most innovative and cutting-edge solutions to problems and issues faced by the healthcare industry. Most of these companies are...
-
Company Profile
Viracta Therapeutics Inc – Company Profile
Viracta Therapeutics Inc (Viracta Therapeutics), develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's pipeline products include Nana-val for the treatment of Lymphoma and Solid Tumors; SSN-510 for the treatment of hematology and solid tumors. The company had partnered programs under development include TAK-580 (formerly MLN2480) and Vosaroxin for the treatment of various types of cancer. The company entered into partnership with Biogen, Takeda, DOT Therapeutics-1, Inc, Denovo Biopharma, LLC for the development of...
Add to Basket -
Product Insights
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha 2C Adrenergic Receptor (ADRA2C) Drugs in Development Report Overview Alpha-2C adrenergic receptor or ADRA2C plays a critical role in regulating neurotransmitter release from sympathetic nerves and adrenergic neurons in the central nervous system. The Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) drugs in development research report provides comprehensive information on the therapeutics under development for ADRA2C. The report also analyzes the stage of development, mechanism of action (MoA), route of...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...
-
Product Insights
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. The condition rarely causes signs or symptoms in the early stages of the disease. The symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding, and frequent infections. The Myelodysplastic Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug...
-
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – liafensine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry liafensine Drug Details Liafensine (BMS-820836) is under development for the treatment of treatment-resistant depression....